CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association Single-Molecule hsTnI and Short-Term Risk in Stable Patients With Chest Pain Myocardial Infarction in Young Women Culprit versus multivessel coronary intervention in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network)

Original ResearchFebruary 26, 2020

JOURNAL:Circulation. Article Link

Phosphoproteomic Analysis of Neonatal Regenerative Myocardium Revealed Important Roles of CHK1 via Activating mTORC1/P70S6K Pathway

Y Fan, XJ Guo, LS Wang et al. Keywords: regenerative myocardium

ABSTRACT


BACKGROUND - In mammalian, regenerative therapy after myocardial infarction (MI) is hampered by the limited regenerative capacity of adult heart, while a transient regenerative capacity is maintained in the neonatal heart. Systemic phosphorylation signaling analysis on ischemic neonatal myocardium might be helpful to identify key pathways involved in heart regeneration. We aimed to define kinase-substrate network in ischemic neonatal myocardium and identify key pathways involved in heart regeneration post ischemic insult.

 

METHODS - Quantitative phosphoproteomics profiling was performed on infarct border zone of neonatal myocardium, and kinase-substrate network analysis revealed 11 kinases with enriched substrates and upregulated phosphorylation levels including CHK1 kinase. The effect of CHK1 on cardiac regeneration was tested on ICR-CD1 neonatal and adult mice underwent apical resection or MI.

 

RESULTS - In vitro, CHK1 overexpression promoted, while CHK1 knockdown blunted cardiomyocyte (CM) proliferation. In vivo, inhibition of CHK1 hindered myocardial regeneration on resection border zone in neonatal mice. In adult MI mice, CHK1 overexpression on infarct border zone upregulated mTORC1/P70S6K pathway, promoted CM proliferation and improved cardiac function. Inhibiting mTOR activity by rapamycin blunted the neonatal CM proliferation induced by CHK1 overexpression in vitro.

 

CONCLUSIONS - Our study indicates that phosphoproteome of neonatal regenerative myocardium could help identify important signaling pathways involved in myocardial regeneration. CHK1 is found to be a key signaling responsible for neonatal regeneration. Myocardial overexpression of CHK1 could improve cardiac regeneration in adult hearts through activating mTORC1/P70S6K pathway, CHK1 might thus serve as a potential novel target in myocardial repair post MI.